BioCryst Pharmaceuticals heads into the post-earnings period with a striking bifurcation: short interest has jumped back toward cycle highs while borrowing costs have crashed to their lowest levels of the year — a combination that paints a picture of conviction on the bear side at bargain-basement terms.
The most notable move in short positioning happened between April 23 and April 27. Short interest as a percentage of the free float leapt from roughly 14.2% to 17.6% — a jump of more than three percentage points in four sessions. That compression followed a period in early April when SI had briefly touched 18.2% before easing. It now runs at 17.4% of the float, putting it back near the upper end of its recent range and well above the mid-April trough. The lending market is not straining under that weight, however. Borrow availability is relatively unconstrained — the lending pool remains well-stocked — and cost to borrow has collapsed from a spike near 4.9% in late April to just 0.49% now, the lowest reading in the 30-day window. That's a sharp reversal: a month ago CTB was running at more than 57% above current levels. Short sellers are rebuilding positions, and doing so cheaply.
Options traders are not adding much bearish fuel. The put/call ratio is running at 0.27, only modestly above its 20-day average of 0.25 and well below the 52-week peak of 0.41. A z-score of 0.72 places the reading barely above neutral. The overall options picture is closer to indifference than alarm — call-side activity continues to dominate the order flow, keeping the ratio structurally low and suggesting options market participants are not amplifying the bearish thesis being expressed through the equity borrow market.
The Street tells a more constructive story than the short book. The analyst community's mean price target runs around $21, more than double the current price of $9.03 — a gap large enough to merit scrutiny, though it does partly reflect a cohort of targets in the $20s-$30s range from firms including HC Wainwright, TD Cowen, Cantor Fitzgerald, JMP Securities, and Needham, most of which were set between October and December 2025. The most recent analyst move came from RBC Capital in late January 2026, trimming its target to $13 while holding an Outperform rating. Barclays has the lone bearish anchor, holding Equal-Weight with a $9 target — essentially pinning the stock at current prices. The bull case centres on Orladeyo's resilience in the HAE market and the long-duration potential of pipeline candidate navenibart. Bears lean on HAE competitive pressure from new long-acting injectables and the risk of Orladeyo losing market share among milder patients. Two factor scores worth noting: EPS surprise ranks in the 99th percentile, and 90-day EPS momentum runs at the 91st — suggesting the company has been consistently outrunning analyst models. The EV/EBIT score (86th percentile) implies the market is giving credit for operational progress even as the PE of around 15x looks modest for a biotech with a growing rare disease franchise.
Institutional ownership shows some active-manager interest worth flagging. Janus Henderson added more than 7.3 million shares in the December 2025 quarter, making it a meaningful new holder at roughly 2.9% of shares outstanding. RA Capital — a specialist healthcare fund — held 6.2% as of year-end. Deerfield Management added 2.2 million shares in the same period. Aberdeen added over 4 million shares through Q1 2026. The passive giants Vanguard and BlackRock also added modestly. No insider buying is visible in the 90-day window. The sell-side of the insider ledger shows net sales worth approximately $4.7 million over 90 days, led by a March sale of 306,000 shares by director Jon Stonehouse — the same individual who also appears in the CEO role in earlier transactions. That level of selling, while not dramatic relative to the share count, warrants monitoring as a signal of management's near-term price comfort zone near $8.60–$10.
Earnings dropped on May 6, with the prior quarter's print (May 4) delivering a one-day move of -1.7%. With results now digested, attention turns to what management communicated on navenibart's development timeline and any updated Orladeyo patient adds — those two datapoints are the variables the short rebuild and the wide analyst target dispersion are essentially betting against each other on.
See the live data behind this article on ORTEX.
Open BCRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
